1. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Issue 11 (November 2020) Authors: Cheson, Bruce D; Bartlett, Nancy L; LaPlant, Betsy; Lee, Hun J; Advani, Ranjana J; Christian, Beth; Diefenbach, Catherine S; Feldman, Tatyana A; Ansell, Stephen M Journal: Lancet Issue: Volume 7:Issue 11(2020) Page Start: e808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗